NorthStar Medical Radioisotopes and Ariceum Therapeutics have signed a supply agreement for therapeutic medical radioisotope actinium-225 (Ac-225), the company announced recently.

According to a release, NorthStar will supply non-carrier added Ac-225, which is a rare and critical isotope, for use with Ariceum’s first-in-class radiopharmaceutical drug called satoreotide.

“Ariceum’s impressive development portfolio is focused on very aggressive, difficult-to-treat cancers, and its early trial results are very exciting,” NorthStar President and Chief Executive Officer Frank Scholz said in a statement. “We are proud to use our expertise and capabilities to provide innovative companies like Ariceum with high purity, non-carrier added Ac-225, that will help make potential new treatment therapies a prospect for the benefit of patients.”

Satoreotide is being developed for the combined diagnosis and targeted radionuclide treatment of multiple indications expressing SSTR2, such as small cell lung cancer (SCLC), pancreatic cancers, Merkel Cell Carcinoma, and other aggressive cancers.